Monoclonal Antibodies In Veterinary Health Market Size, Share & Trends Analysis Report By Application (Dermatology, Pain), By Animal Type (Dogs), By End User (Veterinary Hospitals), By Region, And Segment Forecasts, 2025 - 2030

Monoclonal Antibodies In Veterinary Health Market Summary

Furthermore, rising research and development expenditure by market players is expected to significantly drive growth in the global monoclonal antibodies (mAbs) in the veterinary health market. For instance, in April 2025, Virbac and MabGenesis announced a licensing agreement. Under this agreement, Virbac will develop and commercialize novel canine therapeutic monoclonal antibodies from MabGenesis' advanced phage display and antibody isolation technologies. This collaboration underscores the increasing investment in innovative antibody-based therapeutics targeting complex diseases such as cancer in companion animals.

According to a 2024 report published by the American Pet Products Association (APPA), about 94 million families, i.e., 71% of households in the U.S., owned a pet. As NAPHIA’s 2024 report highlights, the total number of pets insured in the U.S. in 2024 was 6.4 million, a 12.7% increase since 2023. An increase in the number of pet adoption rates has simultaneously increased the health concerns among pet owners, resulting in rising health expenditure on pets. This increasing pet expenditure leads to growing demand for more effective therapeutics, which is anticipated to fuel market growth.

The increasing prevalence of canine atopic dermatitis is also likely to act as a driving factor in market growth. Canine atopic dermatitis is a hereditary clinical syndrome in domestic dogs. Furthermore, dogs' most common cause of itchy allergic skin disease is atopic dermatitis. According to data published by Frontiers Media S.A. in October 2020, the disease is estimated to affect around 10-15% of the canine population. The publication also stated that this number is likely to increase with time. Market players such as Zoetis have products such as Cytopoint, the first monoclonal antibody treatment for allergic and atopic dermatitis.

The increasing incidence of cancer, especially in canines, is expected to positively impact market growth. According to a study published by the Animal Cancer Foundation, 32 million cats and 65 million dogs suffer from tumors in the U.S. Dogs are more likely to suffer from conditions like malignant neoplasia and lymphoma, according to the American Veterinary Medical Association. Moreover, the market is supported by various health initiatives by the government and private organizations, especially focusing on cancer treatment.

Market Concentration & Characteristics

The monoclonal antibodies (mAbs) market in veterinary health demonstrates a high degree of innovation, characterized by developing species-specific, targeted biologics for chronic and previously unmet medical needs in companion animals. This innovation is evident in products like Lokivetmab (Cytopoint), the first USDA- and EMA-approved mAb for canine atopic dermatitis, and Frunevetmab (Solensia), the first mAb therapy for osteoarthritis pain in cats. These biologics offer longer-lasting effects, reduced side effects compared to traditional drugs, and improved quality of life for pets. Companies like Zoetis, Merck Animal Health, and Elanco are driving this innovation, while partnerships such as the one between Nona Biosciences and Invetx in February 2025 are accelerating the discovery of next-generation mAbs using cutting-edge platforms like HCAb Harbour Mice. This collaboration marks Nona's expansion into the veterinary sector, while Invetx will use the platform to accelerate the development of novel monoclonal antibody treatments for companion animals.

The monoclonal antibodies (mAbs) market in veterinary health is witnessing a rising level of merger and acquisition (M&A) activity, driven by growing demand for innovative biologics in companion animal care. A notable example is the 2025 acquisition of Invetx Inc. by Dechra Pharmaceuticals for up to $520 million. This strategic move highlights the increasing value placed on advanced mAb platforms and pipelines targeting chronic conditions such as atopic dermatitis and osteoarthritis in pets. The deal reflects a broader industry trend of consolidating biotherapeutic capabilities to accelerate innovation, expand portfolios, and enhance competitiveness in the rapidly evolving veterinary biopharmaceutical landscape.

The establishment of centralized approval (EU) and bifurcated regulatory control (U.S.) enabled the successful launch of first-in-class veterinary mAbs like Solensia and Librela for osteoarthritis in cats and dogs, respectively. These were among the first mAbs fully licensed for animal use, setting regulatory precedents. Furthermore, regulatory acceptance expanded the pipeline of veterinary mAbs, with dozens of preclinical or clinical development candidates targeting chronic conditions like atopic dermatitis, pain, and infectious diseases in animals.

The product substitutes primarily include traditional therapies such as small-molecule drugs, vaccines, and biologics like recombinant proteins and cytokine inhibitors. For instance, while mAbs like Cytopoint are used to treat atopic dermatitis in dogs, corticosteroids and antihistamines remain common alternatives, although they carry risks of long-term side effects. Similarly, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids are often used to manage osteoarthritis pain in pets, serving as substitutes for anti-nerve growth factor mAbs such as Solensia and Librela. These substitutes offer effective but sometimes less targeted treatments than mAbs, providing more specific, long-lasting solutions with potentially fewer side effects.

The monoclonal antibodies (mAbs) veterinary health market focuses on veterinary clinics, animal hospitals, and research institutions. Veterinary clinics and hospitals are the primary end-users, where mAbs are commonly administered to dogs and cats. Research institutions play a key role in the development and clinical testing of new mAb therapies. The market is also influenced by the growing presence of large veterinary pharmaceutical companies, like Zoetis and Merck, which distribute mAb products through a network of veterinary professionals and clinics. Despite the concentration of end-users in clinical settings, the increasing demand for personalized and advanced treatments is driving broader adoption across various animal healthcare providers.

Animal Type Insights

The dogs segment held the highest revenue share in 2024, owing to the availability of more monoclonal antibody products for dogs in the market. In addition, the population of dogs as pets is also rising, and expenditure on their health is also increasing, which is further boosting the market growth. According to The American Pet Products Association (APPA) 2025 State of the Industry Report, 94 million U.S. households own at least one pet, with 51% of U.S. households (68 million) owning a dog. This highlights the significant cultural and economic importance of dogs as companions. Dogs are often regarded as family members, which fosters a strong demand for preventive care and therapeutic products in developed markets.

The other segment is estimated to witness the fastest growth rate of more than 35.6% over the forecast period. Other animals include cats, horses, and livestock. The rising prevalence of various chronic diseases in animals and the rising adoption of pet insurance are also anticipated to fuel market growth. Furthermore, Pet ownership is regaining momentum, and according to the American Pet Products Association’s 2025 report, 49 million U.S. households, about 37%, own a cat. Cats are becoming increasingly popular, especially in countries like Canada, where they are now often preferred over dogs.

Application Insights

The dermatology segment held the largest revenue share of 51.31% in 2024, owing to various products in this category. In addition, the growing incidences of atopic dermatitis in animals and other infectious skin diseases are expected to boost market growth. According to the article published in the World Veterinary Journal in September 2024, Skin disorders are a significant issue in veterinary medicine globally, with studies showing prevalence rates of 21.4% in the UK, 17% in Iran, and 12%-27.6% in India among dogs. These conditions are a common concern in small animal practices. In addition, environmental changes, such as climate variations, pollution, and allergens, have increased skin-related problems in pets, further driving the demand for monoclonal antibodies used in veterinary dermatology treatment.

The others segment is anticipated to witness the fastest growth rate of 19.9% over the projected period. Other diseases include cancer, arthritis, and various infectious diseases. The fastest growth is attributed to multiple R&D activities to develop innovative treatment options. Furthermore, the pain segment is also expected to account for a significant market share in 2024, owing to various products in the segment.

End User Insights

Veterinary hospitals accounted for the largest revenue share of the market in 2024. This is owing to the presence of novel therapies. Furthermore, the number of veterinary hospitals, along with the number of veterinarians, is rising, which leads to positive market growth. According to a report published by AVMA in 2024, there were 130,415 veterinarians in the U.S.

The others segment is anticipated to grow at the highest CAGR of 20% during the projected period. Other segments include clinics, research organizations, and academic institutes. Increasing research activities for developing novel monoclonal antibody therapeutic options is also anticipated to fuel market growth. Furthermore, growing awareness regarding advanced veterinary therapeutic alternatives is also estimated to boost market growth.

Regional Insights

North America captured the largest market share of 43.775% in 2024.The North America monoclonal antibodies in veterinary health market is driven by increasing pet ownership and the deepening human-animal bond. According to the 2024 AVMA Pet Ownership and Demographic Sourcebook, dog-owning households in the U.S. have surged from 31.3 million in 1996 to 59.8 million in 2024, while cat-owning households increased from 27 million to 42.1 million in the same period. As 89% of dog owners and 85% of cat owners now view pets as family, spending on preventive healthcare, including advanced treatments like monoclonal antibodies, has increased, with average pet-related expenditures reaching $1,516 per household in 2024.

U.S. Monoclonal Antibodies In Veterinary Health Market Trends

The U.S. veterinary monoclonal antibodies market is rapidly growing, driven by the increasing adoption of biological therapies for chronic and acute animal diseases like osteoarthritis and infectious conditions such as parvovirus. Innovations in targeted treatments, such as Elanco's CPMA and Zoetis' Librela, are expanding therapeutic options, improving outcomes, and reducing treatment times. For instance, in April 2025, Elanco Animal Health highlighted the success of its Canine Parvovirus Monoclonal Antibody (CPMA) treatment on National Parvo Awareness Day, reporting a 93% survival rate and faster recovery for infected puppies. The company aims to save 1 million puppies by 2030 and is expanding CPMA availability nationwide, supported by its real-time parvo tracking tool, ParvoTrack. Elanco's CPMA sets a precedent as the first USDA conditionally approved monoclonal antibody treatment for canine parvovirus, showcasing the potential of targeted biologics in emergency veterinary care. Its real-world efficacy and proactive distribution model will likely drive broader acceptance and investment in monoclonal antibody therapies within the U.S. veterinary market.

Europe Monoclonal Antibodies In Veterinary Health Market Trends

Europe monoclonal antibodies veterinary health market is projected to grow steadily, driven by rising pet ownership and increasing pet care spending. According to the 2024 FEDIAF report, 50% of European households own 166 million pets out of 352 million, with a growing dog population fueling demand for advanced veterinary treatments. This trend supports consistent market expansion for monoclonal antibody therapies and related services.   

The UK monoclonal antibodies in veterinary health market is projected to grow significantly over the forecast period, owing primarily to the large pet population, increasing pet ownership, and rising incidence of chronic diseases in pets. According to the PDSA PAW Report 2024, 51% of UK adults own a pet, of which 28% of UK adults have a dog (estimated population of 10.6 million pet dogs), and 24% have a cat (estimated population of 10.8 million pet cats).  Rising product launches & collaborations by major players in the country are estimated to boost market growth. For instance, in July 2024, Dechra Pharmaceuticals acquired US-based Invetx for up to $520 million, gaining access to its innovative monoclonal antibody (mAb) platform for chronic companion animal conditions.

Asia Pacific Monoclonal Antibodies In Veterinary Health Market Trends

The Asia Pacific monoclonal antibodies in veterinary health market is rapidly expanding and is expected to grow significantly during the forecast period. Key drivers include the rising middle-class population, increasing pet adoption, higher pet care spending, and the growing trend of pet humanization. Strong government support and the presence of significant industry players further boost the market, especially in countries like China and India, which are expanding their veterinary facilities. Additionally, greater awareness of pet treatments, surgeries, and pet insurance is fueling demand. The region has many market players involved in strategic partnerships, expansions, product launches, and other initiatives to cater to the growing market demand. For instance, in July 2024, Protect Animal Health (PAH) and DotBio formed a strategic partnership to develop advanced antibody-based therapies for dogs and cats, leveraging DotBio's DOTBODY technology to address chronic diseases like cancer and autoimmune disorders.

India monoclonal antibodies in the veterinary health market are rapidly growing, driven by rising pet ownership, increasing disposable incomes, and greater awareness of advanced veterinary treatments. Strategic collaborations, such as Biocon's Syngene International partnering with Zoetis to produce canine osteoarthritis mAbs and significant contributions from Indian Immunologicals Limited in vaccine production, fuel market expansion. The growth is further supported by expanding veterinary hospital infrastructure, highlighted by the launch of India’s first large-scale small animal hospital in Mumbai and increased adoption of pet insurance. For instance, in February 2024, Tata Trusts launched India's first small animal hospital in Mumbai. It is the first of its kind, spans over 98,000 sq ft across five floors, and has a capacity of 200+ beds. The facility would provide services with a mission to save lives. Changing attitudes toward pets as family members and rising demand for quality pet care and surgeries are key market drivers.

Latin America Monoclonal Antibodies In Veterinary Health Market Trends

The Latin American monoclonal antibodies in the veterinary health market are experiencing robust growth, driven by increasing pet ownership, rising disposable incomes, and heightened awareness of advanced veterinary treatments. Rising pet ownership is one of the most prominent drivers, especially in urban centers across Brazil and Argentina. According to the Brazilian Institute of Geography and Statistics (IBGE), Brazil alone has over 149 million pets, including dogs, cats, birds, and other animals. This rise is mainly due to urbanization, lifestyle changes, and the growing emotional bond between people and their pets, often called the "humanization of pets." As more households treat pets as family members, demand for veterinary care, including monoclonal antibody treatment, has grown significantly.

Argentina monoclonal antibodies in the veterinary health market are steadily growing, fueled by rising pet ownership, with about 78% of households owning pets, 63% dogs, and 26% cats, per the Argentina Pet Food Manufacturers Association. Increasing disposable incomes have boosted spending on advanced veterinary care and premium products. Urbanization and smaller family sizes have enhanced the emotional bond with pets, driving demand for high-quality healthcare solutions in major cities like Buenos Aires, Córdoba, and Rosario. Average annual veterinary expenses per pet range between 15,000 and 20,000 Argentine pesos, supporting market expansion.

MEA Monoclonal Antibodies In Veterinary Health Market Trends

The Middle East and Africa (MEA) monoclonal antibodies in the veterinary health market are witnessing strong growth, driven by rising pet ownership, higher disposable incomes, and growing awareness of animal healthcare. Key countries such as South Africa, Saudi Arabia, the UAE, and Kuwait are seeing rapid increases in pet adoption, influenced by changing social trends and urbanization. For example, the pet population in the UAE is projected to grow at an annual rate of 9.5%, boosting demand for advanced veterinary treatments, pharmaceuticals, and specialized care products across the region.

The South African monoclonal antibodies in the veterinary health market are growing due to increasing animal health concerns, well-developed infrastructure, and rising demand for veterinary care. With 59% of households owning pets, dogs being the most common at 78%, there is a strong need for advanced veterinary products and services. Pet owners in South Africa typically spend between USD 1,800 and USD 4,000 annually on pet care, driven by rising disposable incomes among the middle class. Additionally, veterinary service expenditures have grown by 12% from 2019 to 2023, indicating a steady increase in investment toward pet health and wellness.

Key Monoclonal Antibodies In Veterinary Health Company

The monoclonal antibodies in the veterinary health market are competitive. Key companies deploy strategic initiatives, such as product development and launches, sales & marketing strategies to increase product awareness, regional expansion, and partnerships to strengthen their market share. For instance, in July 2024, Invetx Inc., a biotech firm specializing in monoclonal antibody therapeutics for pets, announced its planned acquisition by Dechra Pharmaceuticals for up to $520 million, pending regulatory approvals. The deal will enhance Dechra’s portfolio in companion animal health and give it access to Invetx’s innovative half-life extension platform for longer-acting treatments.

Recent Developments

• In April 2025, Virbac licensed novel monoclonal antibodies from Japan-based MabGenesis to develop therapeutic treatments for canine diseases. Under the agreement, MabGenesis will receive licensing fees, milestone payments, and royalties, while Virbac will leverage the technology to expand its veterinary treatment portfolio.

• In February 2025, Zoetis updated the U.S. label for Librela (bedinvetmab injection), a once-monthly treatment for canine osteoarthritis pain, based on post-approval real-world data. With over one million dogs treated in the U.S. since its 2023 launch, Zoetis reaffirms the product's safety and effectiveness while providing enhanced resources and support for veterinarians and pet owners.

• In October 2024, Elanco shared real-world data showing its Canine Parvovirus Monoclonal Antibody (CPMA) significantly improved survival rates of 93% in puppies treated for parvovirus while reducing hospital stays and clinic stress. As the first USDA Conditionally Approved targeted treatment for parvovirus, CPMA is transforming veterinary care and aligns with Elanco's mission to save one million puppies by 2030.

Monoclonal Antibodies In Veterinary Health Market Report Scope

Global Monoclonal Antibodies In Veterinary Health Market Report Segmentation

This report forecasts revenue growth at the global, regional & country level and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global monoclonal antibodies in the veterinary health market report based on animal type, application, enduser, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Dermatology

  • Pain

  • Others

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Dogs

  • Others

• End User Outlook (Revenue, USD Million, 2018 - 2030)

  • Veterinary Hospitals

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

    • Rest of Europe

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

    • Rest of Asia Pacific

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of Middle East & Africa